Fig. 2From: A revised compartmental model for biokinetics and dosimetry of 2-[18F]FDGDecay-corrected TACs in source regions predicted by the proposed biokinetic model along with the experimental data (scattered points; decay-corrected to the time of injection). For comparison, TACs reported in MIRD dose estimate report 19 [3] are given in dashed lines. For liver, lungs, pancreas and spleen, the TACs predicted by the proposed model for organ parenchyma only (i.e. without organ blood content) are shown in dotted lines. Activity of 2-[18F]FDG is given in % of administered activityBack to article page